Avesthagen Limited, a global leader in information technology, consulting, and business process outsourcing, has formed a four-year strategic partnership with Wipro Limited to commercialize its genetic testing portfolio. The genome panels in the portfolio provide highly specific, disease-centric analysis for cancer, neurodegenerative diseases, autoimmune disorders, and rare disease conditions.

Avesthagen and Wipro will collaborate on the project "Cancer Risk Assessed by NGS Profiling of Circulating free DNA and RNA for Lung Cancer Project Related Genomics Sequencing Services." The project will be co-led by Avesthagen and Wipro, with Wipro's cutting-edge Lifesciences lab performing initial sample processing, generating data on the latest Next-generation sequencing platforms, compiling genomic sequences, and analyzing detailed molecular information using computational AI/ML tools.

Wipro's expertise in genomics and biomarker discovery will assist Avesthagen in developing well-regulated workflows during the development of CALiBRx® gene panels.  The tests would primarily be available in oncology-focused super specialty clinics and hospitals. Later, it will strategically release diagnostic tools for upper respiratory cancers such as head, neck, and esophageal cancers. The project would result in a new generation of genome-led medicine in the medium and long term.

"Genomics-based innovation is in Avesthagen's DNA." The Avestagenome Project, which began in 2008, is the world's largest epidemiological study of a consanguineous population.  "The diagnostic tools portfolio that we are launching today is the result of the collective knowledge that we have amassed since, and we are excited to work with WIPRO to bring clinical genetics-based precision diagnostics to the people," says Dr. Villoo Morawala-Patell, Founder, Chairman, and Managing Director, Avesthagen Limited. 

The 624 gene panel CALiBRxO will be available in the market in Q3 2022 and will be used to treat cancers and neurological conditions. It presents a targeted screening approach of 624 genes implicated in oncological conditions.